Science Corporation is preparing for its first human brain sensor placement, marking a pivotal step in the company’s effort to bridge the gap between biological neurons and electronic hardware. The initiative will be led by Murat Günel, the chair of the Department of Neurosurgery at the Yale School of Medicine and neurosurgeon-in-chief of Yale New Haven Health.
The device is a pea-sized chip featuring 520 recording electrodes. Unlike the invasive approach used by some competitors, this sensor will not be embedded into the brain tissue. Instead, It’s designed to rest on the surface of the cortex, capturing neural activity from the exterior. The company plans to integrate these placements into surgeries that are already scheduled for other medical reasons, such as a craniectomy to relieve swelling in a stroke patient.
Founded by Max Hodak, the former president of Neuralink, Science Corp is positioning itself as a distinct alternative in the brain-computer interface (BCI) landscape. By utilizing an “opportunistic” surgical approach, the company aims to evaluate the sensor’s safety and signal-recording capabilities with minimal additional risk to patients. Whereas the company has described a timeline for beginning broader trials in 2027, Günel has characterized that estimate as “optimistic.”
The strategy avoids the immediate need for FDA approval for these initial placements, as the company argues the device poses no significant risk during major existing surgeries. Instead, the project will move forward through institutional review boards (IRBs), the ethics committees responsible for overseeing human research at academic medical centers.
The Biohybrid Vision: Beyond Traditional Electrodes
While the first human placement will be a recording-only device, it serves as the foundation for a more ambitious “biohybrid” interface. The long-term goal of Science Corp is to create a device embedded with lab-grown neurons that have been genetically modified with light-sensitive proteins. In this architecture, micro-LEDs on the chip trigger these neurons to fire, while nearby electrodes detect the activity.
This biological layer is intended to integrate naturally with a patient’s own brain cells over time, essentially creating a living bridge between electronics and neural tissue. This differs fundamentally from the current BCI race, where companies are primarily refining how synthetic electrodes interact with existing neurons. Science Corp is betting that growing new neurons that natively “speak” both biological and electronic languages will provide a superior interface.
This biological integration remains unproven in humans and has only been demonstrated in laboratory settings. The upcoming sensor placement is designed to prove the hardware platform can capture usable signals from the cortical surface before the company attempts to introduce the biological components.
Diversifying the Portfolio: The PRIMA Retinal Implant
The brain sensor is the second major front for the company. Science Corp has already seen significant progress with PRIMA, a retinal implant aimed at restoring vision for patients suffering from geographic atrophy caused by age-related macular degeneration.
The PRIMA device is a photovoltaic chip measuring 2mm by 2mm and approximately 30 micrometres thick—roughly half the width of a human hair. It sits beneath the retina and is powered wirelessly by specialized glasses that project near-infrared light. The efficacy of the device was detailed in the New England Journal of Medicine in October 2025, reporting that 38 patients across 17 clinical sites saw an average improvement of 25.5 letters on a standard eye chart after 12 months. According to the study, 84 percent of patients regained the ability to read letters, numbers, and words.
The PRIMA implant has already received FDA breakthrough device designation. The company has submitted an application for a CE mark in the European Union and expects approval by mid-2026.
A Comparative Landscape of BCI Strategies
Science Corp enters the human trial phase at a time when the BCI sector is diversifying its technical bets. Each major player is pursuing a different philosophy regarding how to access the brain’s data.
| Company | Primary Technical Bet | Surgical Approach | Core Objective |
|---|---|---|---|
| Science Corp | Biohybrid (Lab-grown neurons) | Cortical Surface | Biological-Electronic Integration |
| Neuralink | Electrode Density &. Automation | Invasive Implant | High-bandwidth Neural Control |
| Synchron | Vascular Delivery | Endovascular (Stentrode) | Surgical Simplicity/Safety |
| Paradromics | Raw Data Bandwidth | Invasive Implant | High-speed Speech Restoration |
Neuralink has already implanted its N1 device in over 20 patients and is moving toward high-volume production and automated surgery in 2026. Synchron has taken a less invasive route, deploying its Stentrode through blood vessels to allow patients with ALS to control digital devices. Meanwhile, Paradromics is targeting speech restoration with a system claiming transfer rates exceeding 200 bits per second.
Funding and Organizational Scale
To support these dual tracks of ocular and neural interfaces, Science Corp has secured substantial financial backing. In March 2026, the company closed a $230 million Series C funding round led by Lightspeed, with participation from Khosla Ventures, Y Combinator, Quiet Capital, and IQT, the strategic investment arm of the U.S. Intelligence community.
This round valued the company at $1.5 billion, bringing its total funding to $490 million. The organization currently employs 150 people, balancing the technical expertise of founder Max Hodak with the clinical authority of Dr. Murat Günel.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Brain-computer interface technologies are currently in experimental and clinical trial stages.
The next critical checkpoint for Science Corp will be the completion of the initial sensor placements and the subsequent review by institutional boards to determine if the hardware is safe for wider clinical trials. The company’s ability to transition from a recording-only device to a biohybrid system will depend on these early safety outcomes and the eventual pursuit of regulatory pathways for biological implants.
We invite readers to share their thoughts on the future of biohybrid interfaces in the comments below.
